Interferon was characterized as an antiviral entity by Isaacs et al. (1, 2) in 1957. Since that time a vast literature on interferon has accumulated (see refs. 3-5 for reviews). Viruses, isolated double-stranded RNA, and other compounds have been found to stimulate interferon synthesis by cells. Interferon production serves as a valuable model of induced protein synthesis in eukaryotic cells. At present, however, relatively little is known about the molecular mechanisms of interferon induction and biosynthesis. To study interferon biosynthesis and gene expression, we have partially purified interferon messenger RNA from human fibroblasts and have translated this mRNA in a cell-free system from mouse cells with the resultant production of biologically active human interferon.
MATERIALS AND with poly(I)-poly(C) by phenol extraction and oligo(dT)-cellulose chromatography as described (8, 9) .
Cell-Free Protein Synthesis with mRNA Fractions in Mouse Ehrlich Ascites Extracts. Messenger RNA fractions were translated in a mouse Ehrlich Ascites cell-free extract as described (8, 9) . Each 0.050-ml reaction mixture contained the following components: 0. 15 The RNA fractions were prepared from induced and uninduced human fibroblasts as described in Materials and Methods. All the RNA preparations were fractionated on oligo(dT)-cellulose into flow through, 0.1 M KCl wash, and KCl-free wash [poly(A)-containing bound mRNA] fractions as reported (8, 9) . Cell-free incubations and interferon assays were performed as described in Materials and Methods. All assays were performed in duplicate. Assays in the absence of RNA and in the presence of RNA from induced cells were performed in quadruplicate. All samples listed as <16 were negative at the lowest dilution that could be tested.
forming the interferon assays were not aware of the composition of the cell-free reaction mixtures.
Neutralization of Interferon. Interferon, prepared in the cell-free extracts, was neutralized with the use of rabbit antiserum to human interferon as described (11, 12) .
Inhibition of Interferon Activity in Cells Treated with Actinomycin D. Human fibroblasts (FS-7 cell strain) were seeded into the wells of a Micro Test II plastic tissue culture plate (30,000 cells per well). Two days after seeding, the cells in two wells were treated for 30 min with actinomycin D (2 gg/ml in 100,gl of MEM) while two wells received the same medium without actinomycin D. After 30 min the cultures were washed. One actinomycin D-treated and one control culture were incubated for 6 hr with 100 ,l of the cellfree product, diluted 1/20 in MEM containing 5% fetal bovine serum (giving a final concentration of 4 reference units of interferon per ml). The two remaining cultures (one actinomycin D-treated and one control) were incubated in medium without interferon. The wells were then washed and inoculated with the Indiana type of vesicular stomatitis virus (about 3 PFU per cell). The virus was allowed to adsorb for 1 hr and the cells were then washed four times to remove unadsorbed virus. Each culture was replenished with 200 M1 of MEM containing 5% fetal bovine serum. Culture fluids were collected 18 hr after virus inoculation, and the yields of virus were determined by plaque titration in cultures of mouse L cells.
RESULTS

Synthesis of human interferon in cell-free extracts
RNA fractions were prepared from induced and uninduced human FS-4 fibroblasts. Induced cells were stimulated with poly(I)-poly(C) and cycloheximide as described in Materials and Methods. Uninduced cells were treated with cycloheximide only or not treated. Fractions not containing poly(A), which passed directly through oligo(dT)-cellulose (flow through), as well as poly(A)-containing fractions, which were bound to oligo(dT)-cellulose, were translated in a cellfree ascites system ( Table 1 ). The results indicate that interferon activity (68 units/ml) was synthesized only in the cell-'free extracts directed by poly(A)-containing fractions from induced human fibroblasts. RNA fractions not bound to the oligo(dT)-cellulose from induced human fibroblasts and all fractions from uninduced human fibroblasts stimulated no detectable synthesis of human interferon activity in the cellfree extracts (Table 1 ). All fractions from mouse plasmacytoma cells (data not shown) stimulated no detectable synthesis of human interferon activity in the cell-free extracts. Evidence for de novo synthesis of human interferon The interferon activity formed in the cell-free incubations dependent on exogenous mRNA could represent de novo synthesis of interferon or, possibly, interferon or poly(I)-poly(C) carried over in the oligo(dT)-cellulose bound fraction. To differentiate between these alternatives, interferon activity was examined in cell-free reactions in the presence and absence of the 60 min incubation at 30°( Table 2 ). The data show that only reaction mixtures incubated at 300 for 60 min yielded interferon activity. In addition, sparsomycin, a specific inhibitor of protein synthesis (13) , abolished the synthesis of human interferon in these cell-free extracts (Table 2) . Species specificity of human interferon synthesized in the cell-free system Interferons exhibit species specificity (3) (4) (5) The mRNA was prepared from induced human fibroblasts and fractionated on oligo(dT)-cellulose as described in Materials and Methods. The mRNA fraction eluted from oligo(dT)-cellulose in the absence of KCl was used. Cell-free incubations and interferon assays were performed as described in Materials and Methods. All assays were performed in duplicate.
or mouse cells. The material synthesized in the cell-free mouse extracts with mRNA from induced human fibroblasts was active with human cells, but not in chick or mouse cells (Table 3 ). This species specificity was thus consistent with the activity synthesized being identical to human interferon. Neutralization of human interferon with antisera against interferon Rabbit antisera prepared against human FS-4 cell interferon were shown to neutralize the activity of homologous human interferon (11) . The same-antisera exerted no neutralizing activity against interferons from some heterologous human cells (12) . Thus, it was determined if the activity synthesized in the cell-free extract could be neutralized with antiserum prepared against FS-4 human interferon. The antiviral activity synthesized in the cell-free extract was indeed neutralized with this antiserum (Table 4 ), indicating that the active product is antigenically related to human fibroblast interferon. Approximately the same dilution of antiserum was required for neutralization of human interferon produced by intact FS-4 cells as for neutralization of a comparable quantity of antiviral activity synthesized in the cell-free extract.
Prevention of cell-free interferon activity in cells treated with actinomycin D Activity of interferon can be blocked by treating cells with actinomycin D prior to exposure to interferon (3) (4) (5) . Thus, the ability of actinomycin D to prevent interferon action provides another criterion for identification of the cell-free The neutralization titer is expressed as the highest dilution of antiserum prepared against human fibroblast interferon neutralizing 10 reference units of interferon activity per ml. The cell-free product was prepared with the use of mRNA preparedfrom human fibroblasts treated with poly (I)-poly(C). The standard interferon preparation was produced by intact human FS-4 cells stimulated with poly(I).poly(C) as described (6). activity. The data of Table 5 demonstrate that prior treatment of cells with actinomycin D blocked the antiviral activity synthesized in the cell-free extract.
DISCUSSION
The results demonstrate that mRNA for human interferon can be isolated from human fibroblasts stimulated by poly(I)-poly(C). This mRNA was used in a cell-free mouse extract to produce biologically active human interferon.
The following evidence indicates we have synthesized human interferon de novo: synthesis of interferon was dependent on addition of mRNA from induced human fibroblasts, and synthesis required incubation at 300. In addition, a specific inhibitor of protein synthesis, sparsomycin, abolished synthesis of interferon.
The antiviral activity synthesized had the species specificity characteristic of interferon. It was active on human cells, but not on chick or mouse cells. In addition, specific antiserum against human fibroblast interferon inactivated the activity synthesized in the mouse cell-free extract. Furthermore, as with interferon, the antiviral activity of the cellfree synthesized material was not expressed in cells treated with actinomycin D. The results, therefore, are consistent with the de novo synthesis of human interferon in a cell-free extract from mouse cells. We have used a tracer amount of radioactivity in these experiments (see Table 3 legend). With the use of a greater number of labeled amino acids of high specific activity, highly labeled interferon could be synthesized.
While this work was in progress, Reynolds, Zicha, and Pitha (14) also reported the cell-free synthesis of human in- The ability of actinomycin D to prevent the action of interferon was determined as described under Materials and Methods. The cell-free product was identical to the preparation used in Table 4 . The translational product in the ascites cell-free extract was diluted 1/20 directly into MEM containing 5% fetal bovine serum.
terferon. Previously, RNA isolated from cells induced to produce interferon was used to produce interferon in heterologous intact cells (15) (16) (17) . It was concluded in those studies that mRNA for interferon was translated in the heterologous intact cells.
The results demonstrate that biologically active human interferon can be synthesized in cell-free extracts. Biochemical and physical characterization of the cell-free product will serve to answer whether it is synthesized as a precursor and whether carbohydrate substitutions are required for full biological activity as was suggested previously (11). We do not know whether the active cell-free product was glycosylated. Study of interferon mRNA in stimulated and unstimulated fibroblasts should provide some insight into the control and mechanism of interferon biosynthesis. In general, the ability to isolate and translate interferon mRNA in a cell-free system will permit us to investigate the biosynthesis of interferon and its gene expression.
In addition, human interferon may be the first biologically active eukaryotic protein synthesized in a cell-free system dependent on exogenous mRNA. The synthesis of a biologically active protein indicates that the cell-free system not only is capable of synthesizing the primary amino acid sequence, but also has the capacity for performing those posttranslational processes, if any, required for producing a biologically functional molecule. In the cell-free system all these processes can be delineated.
